Form 4: Alignment Healthcare CEO Sells 180,000 Shares

Alignment Healthcare CEO John E. Kao sold 180,000 shares of common stock for approximately $3.42 million under a pre-arranged 10b5-1 trading plan.

Summary

• John E. Kao, Chief Executive Officer and Director of Alignment Healthcare, Inc. (ALHC), disposed of 180,000 shares of the company's common stock.
• The transaction occurred on December 10, 2025, and was executed pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2025.
• The shares were sold at a weighted-average price of $19.0179 per share, with individual transaction prices ranging from $18.84 to $19.46.
• The total value of the shares sold amounts to approximately $3,423,222.
• Following this transaction, Mr. Kao directly holds 2,839,942 shares and indirectly holds 2,346,726 shares through the JEK Trust.

Sentiment

Score: 4

Explanation: The sale by the CEO, even under a 10b5-1 plan, is generally a bearish signal, though the pre-planned nature mitigates some of the immediate negative impact. It represents a reduction in insider equity exposure.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating the transaction was scheduled in advance and not based on recent material non-public information, which can mitigate the negative perception of insider selling.

Negatives

• A significant sale of 180,000 shares by the Chief Executive Officer, even under a 10b5-1 plan, can be perceived negatively by investors as it reduces the insider's direct equity exposure to the company.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• John E. Kao indirectly holds 2,346,726 shares through the JEK Trust, dated February 8, 2021, of which he is the trustee.

Stakeholder Impact

• Shareholders: May interpret the CEO's share sale as a negative signal, potentially leading to downward pressure on the stock price due to concerns about insider confidence.

Key Dates

Recommendation

The sale of 180,000 shares by CEO John E. Kao, while significant, was executed under a pre-arranged Rule 10b5-1 plan. This suggests the decision was made without reliance on current material non-public information, which mitigates some of the typical negative implications of insider selling. However, it still represents a reduction in the CEO's direct equity exposure. Investors should monitor the stock's performance and any subsequent company announcements, but a 'hold' recommendation is appropriate given the context of a planned sale rather than an opportunistic one.

Keywords

Alignment Healthcare, ALHC, John E. Kao, CEO, insider trading, Form 4, stock sale, 10b5-1 plan, beneficial ownership, common stock